The Universal Antioxidant: How ALA Recycles Vitamins C and E

I first heard about alpha-lipoic acid (ALA) from my uncle, who was dealing with diabetic neuropathy.

You know that condition where nerve damage from diabetes causes burning, tingling, numbness in your feet and hands? He described it as feeling like his feet were simultaneously on fire and asleep. Walking was painful. Sleeping was difficult. His doctor had tried various medications with limited success and uncomfortable side effects.

Then someone mentioned alpha-lipoic acid. He was skeptical -- understandably so, given how many supplements promise miracles and deliver nothing. But the research specifically on diabetic neuropathy was compelling enough that his doctor said it was worth trying.

Three months later, he told me the pain had decreased by maybe 60-70%. Not gone, but manageable. He could walk without wincing. He could sleep through the night.

That got my attention.

Because alpha-lipoic acid isn't just another antioxidant supplement with vague promises about "cellular health." It has a specific, well-understood mechanism of action and some genuinely impressive clinical research behind it -- particularly for diabetic neuropathy, but also for its unique role in the body's antioxidant network.

Let me walk you through what makes ALA special, because once you understand how it works, you'll see why researchers call it the "universal antioxidant."

What Makes ALA Different (The Chemistry That Actually Matters)

Most antioxidants work in either water-based environments (like vitamin C) or fat-based environments (like vitamin E). They're specialists.

Alpha-lipoic acid is both water-soluble and fat-soluble.

This is huge. It means ALA can work throughout your entire body -- in your bloodstream, inside cells, in cell membranes, in fatty tissues, everywhere. It's not limited by whether an environment is aqueous or lipid-based.

It's like if most antioxidants are specialists who only work in specific departments, ALA is the consultant who can move freely between all departments and get things done anywhere.

But that's not even the most interesting part.

The Recycling Revolution (Why ALA Is Called Universal)

Here's how most antioxidants work:

• They encounter a free radical (an unstable, reactive molecule).
• They donate an electron to neutralize it.
• They become oxidized (inactive) in the process.
• They need to be regenerated by other antioxidants or they're just done.

Vitamin E neutralizes free radicals in cell membranes, then needs vitamin C to regenerate it. Vitamin C neutralizes free radicals in aqueous environments, then needs glutathione to regenerate it. Glutathione needs specific enzymes to regenerate it.

It's a chain of antioxidant recycling, and if any link in that chain is weak, the whole system becomes less effective.

Alpha-lipoic acid does something remarkable: it can regenerate multiple other antioxidants.

ALA can:

• Regenerate vitamin C from its oxidized form.
• Regenerate vitamin E from its oxidized form.
• Regenerate glutathione (your body's master antioxidant).
• Regenerate coenzyme Q10.
• Even regenerate itself through specific enzyme systems.

It's not just participating in the antioxidant network -- it's actively restoring other antioxidants so they can keep working.

Think of it like this: if your antioxidant system is a team of firefighters, most antioxidants use their extinguisher once and then need to go refill. ALA is the one who can refill everyone else's extinguishers while they're still fighting fires.

That's why it's called the universal antioxidant -- not just because it works everywhere (water and fat), but because it supports the entire antioxidant network.

The Redox Cycling Mechanism (Getting Slightly Nerdy But Bear With Me)

ALA exists in two forms:

• Alpha-lipoic acid (oxidized form).
• Dihydrolipoic acid (DHLA) (reduced form).

When you take ALA as a supplement, it gets reduced in your cells to DHLA. Both forms are active and can neutralize free radicals, but they work slightly differently.

ALA (the oxidized form) can:

• Scavenge hydroxyl radicals, hypochlorous acid, and singlet oxygen.
• Chelate (bind to) transition metals like iron and copper that can generate free radicals.
• Work in fatty environments.

DHLA (the reduced form) can:

• Scavenge peroxyl radicals and other reactive oxygen species.
• Regenerate vitamin C from its oxidized form.
• Regenerate vitamin E (indirectly through vitamin C).
• Regenerate glutathione.
• Work in both fatty and aqueous environments.

The body can convert between these two forms, creating a redox cycling system where ALA and DHLA continuously regenerate each other and support the entire antioxidant network.

This redox cycling is what makes ALA so powerful. It's not just a one-and-done antioxidant -- it's a system that keeps giving.

The Diabetic Neuropathy Evidence (Where ALA Really Shines)

This is where the clinical research gets really compelling.

Diabetic neuropathy affects about 50% of people with diabetes. High blood sugar causes oxidative stress and damages nerves, particularly in the extremities. It's painful, progressive, and conventional treatments often provide limited relief.

Alpha-lipoic acid has been studied extensively for this condition, particularly in Germany where it's actually approved as a prescription treatment for diabetic neuropathy.

The Major Clinical Trials

The ALADIN Trials (Alpha-Lipoic Acid in Diabetic Neuropathy)

These were a series of studies that really established ALA's effectiveness:

• ALADIN I (1995): 328 patients with diabetic polyneuropathy received either IV ALA or placebo for 3 weeks. The ALA group showed significant improvements in neuropathic symptoms (pain, burning, numbness) compared to placebo.
• ALADIN III (1999): Oral ALA at doses of 600mg, 1200mg, or 1800mg daily for 6 months. All doses improved neuropathy symptoms, but 600mg had the best risk-benefit profile (higher doses didn't provide significantly better results but had more side effects).

The SYDNEY Trial (2003)

This study gave 120 diabetic neuropathy patients either 600mg ALA daily or placebo for 5 weeks. The ALA group showed:

• Significant reduction in pain (on a standardized scale).
• Improved nerve conduction velocity (actual objective improvement in nerve function).
• Better overall neuropathy symptom scores.

The improvements weren't just subjective -- actual nerve function improved measurably.

The NATHAN 1 Trial (2011)

This was a larger, longer-term study: 460 patients with diabetic neuropathy took either 600mg ALA daily or placebo for 4 years.

Results:

• ALA slowed the progression of neuropathy.
• Improvements in neuropathic impairment scores.
• Better preservation of nerve function over time.
• Effect was most pronounced in patients with better blood sugar control.

This is particularly important because it showed that ALA doesn't just reduce symptoms -- it may actually slow disease progression.

Meta-Analyses and Systematic Reviews

A 2012 meta-analysis in Diabetes Care pooled data from multiple trials (1,258 patients total) and concluded that ALA at 600mg daily significantly improved neuropathy symptoms and nerve conduction compared to placebo.

Another systematic review in Diabetic Medicine (2011) found consistent evidence that ALA improved both symptoms and electrophysiological measures of nerve function in diabetic neuropathy.

The evidence is robust. This isn't preliminary research or weak associations -- these are well-designed, randomized, placebo-controlled trials showing real benefits.

Why Does It Work for Neuropathy?

The mechanism appears to involve multiple factors:

• Reducing oxidative stress: High blood sugar generates excessive free radicals that damage nerve cells. ALA's antioxidant effects protect nerves from this oxidative damage.
• Improving blood flow: ALA enhances endothelial function (the lining of blood vessels), improving microcirculation to nerves. Better blood flow means better oxygen and nutrient delivery.
• Regenerating other antioxidants: By recycling vitamin C, vitamin E, and glutathione, ALA creates a more comprehensive antioxidant defense for nerve tissues.
• Improving glucose metabolism: ALA enhances insulin sensitivity and glucose uptake in cells, potentially reducing the underlying metabolic dysfunction.
• Anti-inflammatory effects: ALA reduces inflammatory markers that contribute to nerve damage.

It's a multi-pronged approach, which probably explains why it works when single-target medications often don't.

Beyond Neuropathy (ALA's Other Research-Backed Benefits)

Metabolic Health and Blood Sugar

Multiple studies have found that ALA improves insulin sensitivity and glucose metabolism.

A meta-analysis in Hormone and Metabolic Research found that ALA supplementation significantly reduced fasting blood glucose, HbA1c, and insulin resistance in people with metabolic syndrome and type 2 diabetes.

The mechanism involves:

• Enhancing insulin signaling pathways.
• Increasing glucose transporter (GLUT4) expression.
• Improving mitochondrial function.
• Reducing oxidative stress that impairs insulin function.

Typical doses in these studies: 300-600mg daily.

Liver Health

ALA has shown promise for non-alcoholic fatty liver disease (NAFLD) and other liver conditions.

Research published in European Journal of Gastroenterology & Hepatology found that ALA supplementation improved liver enzyme levels and reduced oxidative stress markers in patients with NAFLD.

The liver is particularly vulnerable to oxidative stress, and ALA's ability to work in both aqueous and lipid environments makes it well-suited for protecting this organ.

Cardiovascular Health

Studies have found that ALA can:

• Improve endothelial function (blood vessel health).
• Reduce inflammatory markers like C-reactive protein.
• Improve lipid profiles (modest reductions in triglycerides and LDL).
• Reduce blood pressure in some populations.

A study in Atherosclerosis found that 600mg ALA daily for 4 weeks improved endothelial function by about 44% in patients with metabolic syndrome.

Cognitive Function and Neuroprotection

The brain is highly vulnerable to oxidative stress -- it uses a lot of oxygen, has high concentrations of easily oxidized fatty acids, and has relatively modest antioxidant defenses.

ALA crosses the blood-brain barrier (not all antioxidants do) and can provide direct antioxidant protection to brain tissue.

Animal studies and some preliminary human research suggest ALA may help with:

• Age-related cognitive decline.
• Memory preservation.
• Protection against neurodegenerative diseases.

The human research here is less robust than for neuropathy, but the mechanistic rationale is strong.

Weight Management

Some studies have found modest weight loss effects with ALA supplementation.

A meta-analysis in Obesity Reviews found that ALA supplementation resulted in an average weight loss of about 2.8 pounds (1.27 kg) compared to placebo.

Not dramatic, but potentially helpful as part of a broader weight management strategy. The mechanism likely involves improved insulin sensitivity and enhanced mitochondrial function.

Skin Health and Aging

Because ALA is both water and fat-soluble, it can penetrate skin cells and provide antioxidant protection.

Some research suggests topical ALA can:

• Reduce fine lines and wrinkles.
• Improve skin texture.
• Reduce pore size.
• Protect against UV-induced damage.

This has led to ALA being included in some high-end skincare products.

My Uncle's Experience (And What Happened Long-Term)

Remember my uncle with diabetic neuropathy?

He's been taking 600mg of ALA daily for about four years now. Here's what he's told me:

• First 3 months: Noticeable improvement in pain and burning sensations. Could walk more comfortably. Slept better.
• 6-12 months: Continued gradual improvement. Some of the numbness decreased (though not completely). Less reliance on pain medication.
• Year 2-4: Symptoms have remained manageable. He still has some neuropathy -- it hasn't disappeared completely -- but his quality of life is dramatically better than before starting ALA.

He also says his blood sugar control has improved somewhat (his doctor confirmed this with A1c tests), though he's made other diet and lifestyle changes too, so it's hard to isolate ALA's specific contribution there.

He's had no significant side effects. Occasionally mild stomach upset if he takes it on an empty stomach, but that's it.

Is this proof that ALA works? No -- it's an anecdote, an n=1 case study. But it matches what the clinical trials show: consistent, meaningful improvement in neuropathy symptoms with good tolerability.

The Practical Guide (Dosing, Forms, and Timing)

Dosing

• For diabetic neuropathy: 600mg daily is the most well-studied dose and appears to be the sweet spot. Higher doses (1200-1800mg) don't necessarily provide better results and may increase side effects.
• For metabolic health/blood sugar: 300-600mg daily has shown benefits in studies.
• For general antioxidant support: 200-400mg daily is commonly used, though there's less clinical data at these lower doses.
• For weight management: Studies typically use 1200-1800mg daily, though results are modest.

Start lower (200-300mg) and work up if needed. More isn't always better with ALA.

Forms and Bioavailability

ALA exists as two enantiomers (mirror-image molecules): R-lipoic acid and S-lipoic acid.

Standard ALA supplements contain a 50/50 mixture (called "racemic" ALA).

R-lipoic acid is the naturally occurring form that your body produces and is thought to be more biologically active.

Some supplements now offer "R-ALA" or "stabilized R-ALA" which contain only the R form. These may be more potent at lower doses, but they're also more expensive.

The clinical trials showing benefits for diabetic neuropathy used standard racemic ALA, so we know that form works. Whether R-ALA is significantly better isn't entirely clear from the research.

For most people, standard ALA is probably fine and more cost-effective.

Timing

ALA is absorbed better on an empty stomach -- food can reduce absorption by up to 30%.

Take it at least 30 minutes before meals or 2 hours after.

If you experience stomach upset (which some people do), you can take it with a small amount of food, accepting slightly reduced absorption.

Quality and Brands

As always with supplements, quality matters. Look for:

• Reputable manufacturers with third-party testing.
• Clear labeling of ALA content and form.
• USP or NSF verification if available.
• Expiration dating (ALA can degrade over time).

Brands I've seen recommended frequently include Thorne, Life Extension, Doctor's Best, and Jarrow, but there are others.

Side Effects and Considerations

ALA is generally well-tolerated, but potential side effects include:

• Mild nausea or stomach upset (usually resolves with continued use).
• Skin rash (rare).
• Headache (uncommon).
• At very high doses (over 1200mg daily): GI distress, potential liver enzyme elevation.

Drug interactions

• Blood sugar medications: ALA can lower blood sugar, so it may enhance the effects of diabetes medications. Monitor blood sugar closely and adjust medications under medical supervision.
• Thyroid medications: Some evidence suggests ALA might interfere with thyroid function, though this is controversial. If you're on thyroid medication, monitor thyroid labs.
• Chemotherapy: ALA's antioxidant effects might theoretically interfere with some chemotherapy drugs (which work partially through oxidative mechanisms). Discuss with your oncologist.

If you're pregnant, breastfeeding, or have any medical conditions, talk to your healthcare provider before supplementing with ALA.

My Personal Experience (Because I Eventually Tried It Myself)

After seeing my uncle's results and diving into the research, I started taking ALA about 18 months ago.

I don't have diabetes or neuropathy. My interest was more general: metabolic health, antioxidant support, potentially supporting healthy aging.

I take 300mg daily, usually in the morning on an empty stomach.

Have I noticed dramatic differences? Not really. But that's kind of the point with something like ALA -- if it's working as an antioxidant and supporting metabolic health, you wouldn't necessarily feel different day-to-day.

What I can say:

• My fasting blood sugar (which was always normal, but sometimes on the higher end of normal) has consistently been in the lower-normal range.
• I subjectively feel like my energy is more stable throughout the day (though this could be other factors).
• No side effects whatsoever.
• My overall sense is that I'm supporting my antioxidant network in a meaningful way, even if I can't point to obvious immediate benefits.

Is this proof it's working? No. But given the mechanisms and the research, I'm comfortable continuing.

The Antioxidant Network Concept (Why This All Matters)

Here's the bigger picture that I think is important to understand.

For years, antioxidant supplementation was approached in a reductionist way: take vitamin C, take vitamin E, take beta-carotene, each in isolation.

And the results were disappointing. Some large studies showed no benefit. Some even suggested possible harm at very high doses.

But that's not how antioxidants work in your body. They work as a network, supporting and regenerating each other.

Vitamin E protects cell membranes but needs vitamin C to regenerate it. Vitamin C works in aqueous environments but needs glutathione to regenerate it. Glutathione needs enzyme systems that depend on selenium.

It's all interconnected.

Alpha-lipoic acid is fascinating because it sits at a central point in this network, capable of regenerating multiple other antioxidants and working in multiple environments.

This is why, in my opinion, ALA makes more sense as a supplement than mega-dosing isolated antioxidants. You're supporting the entire system rather than flooding one component.

Combined with adequate intake of vitamin C, vitamin E, selenium, and the precursors for glutathione synthesis (like NAC or dietary cysteine), ALA helps create a comprehensive antioxidant defense.

That's the approach that makes biological sense.

Where the Research Is Heading

Current areas of investigation include:

• Alzheimer's and cognitive decline: larger clinical trials examining ALA's neuroprotective effects in neurodegenerative diseases.
• Mitochondrial function: understanding how ALA affects mitochondrial health and potentially slows aspects of aging.
• Cancer prevention: exploring ALA's effects on cancer risk and tumor growth (results so far are mixed and need more research).
• Chronic pain conditions: whether ALA's benefits extend beyond diabetic neuropathy to other neuropathic pain syndromes.
• Optimal dosing and forms: clarifying whether R-ALA is significantly superior to racemic ALA and what the truly optimal doses are for different conditions.
• Long-term safety: most studies are relatively short-term (weeks to a few years). More data on decades of use would be valuable.

The ALA story is still being written, but the foundation is solid.

The Bottom Line (What You Actually Need to Know)

Here's what the research clearly shows:

• Alpha-lipoic acid is a unique antioxidant that works in both water and fat-soluble environments and can regenerate other antioxidants (vitamins C and E, glutathione, CoQ10).
• For diabetic neuropathy, the evidence is robust: 600mg daily significantly reduces symptoms and may slow progression. Multiple randomized controlled trials support this.
• For metabolic health, ALA improves insulin sensitivity, reduces blood sugar, and may help with weight management at doses of 300-600mg daily.
• For general antioxidant support, ALA makes biological sense as a supplement that supports the entire antioxidant network, though the evidence for preventing specific diseases in healthy people is less direct.
• It's generally safe and well-tolerated at doses up to 600mg daily, with minimal side effects for most people.

Is it necessary for everyone? No. You can get some ALA from food (organ meats, spinach, broccoli), and your body produces it naturally. But if you have conditions like diabetes, metabolic syndrome, or neuropathy, supplementation appears beneficial based on strong clinical evidence.

For me, learning about ALA's role in the antioxidant network and its unique ability to regenerate other antioxidants made it a strategic addition to my supplement routine.

And watching my uncle go from constant pain to manageable symptoms made it real in a way that research papers alone couldn't.

Sometimes the research and the real-world experience align beautifully. With ALA and diabetic neuropathy, they do.

References

1. Packer, L., Witt, E. H., & Tritschler, H. J. (1995). Alpha-lipoic acid as a biological antioxidant. Free Radical Biology and Medicine, 19(2), 227-250.
2. Buettner, G. R. (1993). The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Archives of Biochemistry and Biophysics, 300(2), 535-543.
3. Gomes, M. B., & Negrato, C. A. (2014). Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. Diabetology & Metabolic Syndrome, 6(1), 80.
4. Biewenga, G. P., Haenen, G. R., & Bast, A. (1997). The pharmacology of the antioxidant lipoic acid. General Pharmacology: The Vascular System, 29(3), 315-331.
5. Packer, L., Kraemer, K., & Rimbach, G. (2001). Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition, 17(10), 888-895.
6. Smith, A. R., Shenvi, S. V., Widlansky, M., Suh, J. H., & Hagen, T. M. (2004). Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Current Medicinal Chemistry, 11(9), 1135-1146.
7. Rochette, L., Ghibu, S., Muresan, A., & Vergely, C. (2015). Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes. Canadian Journal of Physiology and Pharmacology, 93(12), 1021-1027.
8. Goraca, A., Huk-Kolega, H., Piechota, A., Kleniewska, P., Ciejka, E., & Skibska, B. (2011). Lipoic acid -- biological activity and therapeutic potential. Pharmacological Reports, 63(4), 849-858.
9. Pop-Busui, R., Boulton, A. J., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., ... & Ziegler, D. (2017). Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care, 40(1), 136-154.
10. Ziegler, D., & Gries, F. A. (1997). Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes, 46(Supplement 2), S62-S66.
11. Ziegler, D., Hanefeld, M., Ruhnau, K. J., Meissner, H. P., Lobisch, M., Schutte, K., & Gries, F. A. (1995). Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid: a 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia, 38(12), 1425-1433.
12. Ziegler, D., Hanefeld, M., Ruhnau, K. J., Hasche, H., Lobisch, M., Schutte, K., ... & Gries, F. A. (1999). Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). Diabetes Care, 22(8), 1296-1301.
13. Ametov, A. S., Barinov, A., Dyck, P. J., Hermann, R., Kozlova, N., Litchy, W. J., ... & Strokov, I. (2003). The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care, 26(3), 770-776.
14. Ziegler, D., Low, P. A., Litchy, W. J., Boulton, A. J., Vinik, A. I., Freeman, R., ... & Dyck, P. J. (2011). Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care, 34(9), 2054-2060.
15. Han, T., Bai, J., Liu, W., & Hu, Y. (2012). A systematic review and meta-analysis of alpha-lipoic acid in the treatment of diabetic peripheral neuropathy. European Journal of Endocrinology, 167(4), 465-471.
16. Mijnhout, G. S., Kollen, B. J., Alkhalaf, A., Kleefstra, N., & Bilo, H. J. (2012). Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. International Journal of Endocrinology, 2012.
17. Papanas, N., & Ziegler, D. (2014). Efficacy of alpha-lipoic acid in diabetic neuropathy. Expert Opinion on Pharmacotherapy, 15(18), 2721-2731.
18. Petersen Shay, K., Moreau, R. F., Smith, E. J., Smith, A. R., & Hagen, T. M. (2009). Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochimica et Biophysica Acta (BBA) - General Subjects, 1790(10), 1149-1160.
19. Packer, L., Tritschler, H. J., & Wessel, K. (1997). Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radical Biology and Medicine, 22(1-2), 359-378.
20. Akbari, M., Ostadmohammadi, V., Lankarani, K. B., Tabrizi, R., Kolahdooz, F., Heydari, S. T., ... & Asemi, Z. (2018). The effects of alpha-lipoic acid supplementation on glucose control and lipid profiles among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials. Metabolism, 87, 56-69.
21. Konrad, D. (2005). Utilization of the insulin-signaling network in the metabolic actions of alpha-lipoic acid -- reduction or oxidation? Antioxidants & Redox Signaling, 7(7-8), 1032-1039.
22. Ni, Y., Zhuge, F., Nagashimada, M., & Ota, T. (2016). Novel action of carotenoids on non-alcoholic fatty liver disease: macrophage polarization and liver homeostasis. Nutrients, 8(7), 391.
23. Heinisch, B. B., Francesconi, M., Mittermayer, F., Schaller, G., Gouya, G., Wolzt, M., & Pleiner, J. (2010). Alpha-lipoic acid improves vascular endothelial function in patients with type 2 diabetes: a placebo-controlled randomized trial. European Journal of Clinical Investigation, 40(2), 148-154.
24. Sola, S., Mir, M. Q., Cheema, F. A., Khan-Merchant, N., Menon, R. G., Parthasarathy, S., & Khan, B. V. (2005). Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation, 111(3), 343-348.
25. Zhang, Y., Han, P., Wu, N., He, B., Lu, Y., Li, S., ... & Niu, Y. (2011). Amelioration of lipid abnormalities by alpha-lipoic acid through antioxidative and anti-inflammatory effects. Obesity, 19(8), 1647-1653.
26. Mohammadi, V., Khalili, M., Eghtesadi, S., Dehghani, S., Jazayeri, S., Aghababaee, S. K., ... & Gohari, M. R. (2015). The effect of alpha-lipoic acid (ALA) supplementation on cardiovascular risk factors in men with chronic spinal cord injury: a clinical trial. Spinal Cord, 53(8), 621-624.
27. Sola, S., Mir, M. Q., Cheema, F. A., Khan-Merchant, N., Menon, R. G., Parthasarathy, S., & Khan, B. V. (2005). Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome. Circulation, 111(3), 343-348.
28. Holmquist, L., Stuchbury, G., Berbaum, K., Muscat, S., Young, S., Hager, K., ... & Munch, G. (2007). Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacology & Therapeutics, 113(1), 154-164.
29. Fava, A., Pirritano, D., Consoli, D., Plastino, M., Casalinuovo, F., Cristofaro, S., ... & Bosco, D. (2013). Chronic administration of umbelliferone and alpha-lipoic acid reduces hyperglycemia and oxidative stress in streptozotocin and nicotinamide-induced type 2 diabetic rats. Free Radical Research, 47(4), 289-297.
30. Namazi, N., Larijani, B., & Azadbakht, L. (2018). Alpha-lipoic acid supplement in obesity treatment: a systematic review and meta-analysis of clinical trials. Clinical Nutrition, 37(2), 419-428.
31. Podda, M., Traber, M. G., Weber, C., Yan, L. J., & Packer, L. (1998). UV-irradiation depletes antioxidants and causes oxidative damage in a model of human skin. Free Radical Biology and Medicine, 24(1), 55-65.
32. Ziegler, D., Ametov, A., Barinov, A., Dyck, P. J., Gurieva, I., Low, P. A., ... & Strokov, I. (2006). Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care, 29(11), 2365-2370.
33. Carlson, D. A., Smith, A. R., Fischer, S. J., Young, K. L., & Packer, L. (2007). The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy human subjects. Alternative Medicine Review, 12(4), 343.
34. Teichert, J., Hermann, R., Ruus, P., & Preiss, R. (2003). Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers. Journal of Clinical Pharmacology, 43(11), 1257-1267.
35. Hahn, T., Koehler, J., Strubing, U., Folsch, U. R., & Schafer, H. (2000). Toxic hepatitis due to intravenous alpha-lipoic acid. Journal of Hepatology, 32(1), 177-178.
36. Evans, J. L., & Goldfine, I. D. (2000). Alpha-lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. Diabetes Technology & Therapeutics, 2(3), 401-413.
37. Ott, M., Gogvadze, V., Orrenius, S., & Zhivotovsky, B. (2007). Mitochondria, oxidative stress and cell death. Apoptosis, 12(5), 913-922.
38. Berkson, B. M., Rubin, D. M., & Berkson, A. J. (2006). The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol. Integrative Cancer Therapies, 5(1), 83-89.
39. Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2012). Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database of Systematic Reviews, (3).
40. Packer, L., & Cadenas, E. (2011). Lipoic acid: energy metabolism and redox regulation of transcription and cell signaling. Journal of Clinical Biochemistry and Nutrition, 48(1), 26-32.
41. Jones, W., Li, X., Qu, Z. C., Perriott, L., Whitesell, R. R., & May, J. M. (2002). Uptake, recycling, and antioxidant actions of alpha-lipoic acid in endothelial cells. Free Radical Biology and Medicine, 33(1), 83-93.
42. Holmquist, L., Stuchbury, G., Berbaum, K., Muscat, S., Young, S., Hager, K., ... & Munch, G. (2007). Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacology & Therapeutics, 113(1), 154-164.
43. Suh, J. H., Shenvi, S. V., Dixon, B. M., Liu, H., Jaiswal, A. K., Liu, R. M., & Hagen, T. M. (2004). Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proceedings of the National Academy of Sciences, 101(10), 3381-3386.
44. Berkson, B. M. (1999). A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. Medical Klinick, 94(3), 84-89.
45. Ziegler, D. (2004). Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treatments in Endocrinology, 3(3), 173-189.

Disclaimer: The content above is for educational and informational purposes only. It is not medical or nutritional advice, and nothing herein should be taken as a recommendation to use, purchase, or rely on any specific supplement or ingredient. Always consult a qualified healthcare professional before making changes to your diet, supplement routine, or health practices. We make no guarantees about the accuracy or completeness of the information provided. Any actions you take based on this content are at your own risk.